3 Reasons Pfizer Stock Will Crush the Broader Market in 2022
Pfizer (NYSE: PFE) has been the second-best-performing big pharma stock for the whole of 2021. As of the close of November, the shares were up by an astonishing 45.8% year to date, which is only slightly lower than Eli Lilly's industry-leading 47% gain in 2021.
Pfizer's shares have soared this year due to its dominance in the COVID-19 vaccine market, as well as its late-stage trial success with the oral antiviral pill Paxlovid. In fact, the Pfizer and BioNTech COVID-19 vaccine Comirnaty will likely end 2021 as the best-selling pharmaceutical product of all time from a single-year standpoint.
Despite this sizable jump in 2021, Pfizer seems primed to crush the broader market yet again in 2022. Here are three reasons this top pharmaceutical stock should deliver market-beating returns next year.
Source Fool.com
